Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial.

ABSTRACT:

Background

Glioblastoma (GBM) has a 5-year survival rate of 3%-5%. GBM treatment includes maximal resection followed by radiotherapy with concomitant and adjuvant temozolomide (TMZ). Cytochrome C oxidase (CcO) is a mitochondrial enzyme involved in the mechanism of resistance to TMZ. In a prior retrospective trial, CcO activity in GBMs inversely correlated with clinical outcome. The current Cyto-C study was designed to prospectively evaluate and validate the prognostic value of tumor CcO activity in patients with newly diagnosed primary GBM, and compared to the known prognostic value of MGMT promoter methylation status.

Methods

This multi-institutional, blinded, prospective biomarker study enrolled 152 patients with newly diagnosed GBM who were to undergo surgical rese

SUBMITTER: Griguer CE 

PROVIDER: S-EPMC8788017 | biostudies-literature | 2022 Jan-Dec

REPOSITORIES: biostudies-literature